Alexandros Kourtesakis

Heidelberg, BW 69120, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

A comparative analysis of CD70-directed CAR-T cells for glioblastoma treatment demonstrates a superior efficacy of the ligand-based construct.

A comparative analysis of CD70-directed CAR-T cells for glioblastoma treatment demonstrates a superior efficacy of the ligand-based construct.

Journal: Molecular therapy. Oncology
Published: August 04, 2025

Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma.

Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma.

Journal: Oncoimmunology
Published: June 16, 2025

Distinct epigenetic and transcriptional profiles of Epstein-Barr virus-positive and negative primary CNS lymphomas.

Distinct epigenetic and transcriptional profiles of Epstein-Barr virus-positive and negative primary CNS lymphomas.

Journal: Neuro-oncology
Published: November 22, 2024

Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen.

Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen.

Journal: Nature communications
Published: July 26, 2024

Tumoral Interferon Beta Induces an Immune-Stimulatory Phenotype in Tumor-Associated Macrophages in Melanoma Brain Metastases.

Tumoral Interferon Beta Induces an Immune-Stimulatory Phenotype in Tumor-Associated Macrophages in Melanoma Brain Metastases.

Journal: Cancer research communications
Published: January 11, 2024

NLGN4X TCR transgenic T cells to treat gliomas.

NLGN4X TCR transgenic T cells to treat gliomas.

Journal: Neuro-oncology
Published: September 16, 2023

Integrated genetic analyses of immunodeficiency-associated Epstein-Barr virus- (EBV) positive primary CNS lymphomas.

Integrated genetic analyses of immunodeficiency-associated Epstein-Barr virus- (EBV) positive primary CNS lymphomas.

Journal: Acta neuropathologica
Published: May 28, 2023

A clinically applicable connectivity signature for glioblastoma includes the tumor network driver CHI3L1.

A clinically applicable connectivity signature for glioblastoma includes the tumor network driver CHI3L1.

Journal: Nature communications
Published: January 25, 2023

Autonomous rhythmic activity in glioma networks drives brain tumour growth.

Autonomous rhythmic activity in glioma networks drives brain tumour growth.

Journal: Nature
Published: February 04, 2021
Showing 1-9 of 9

Last Updated: 09/26/2026